Web Analytics
KNSA (NASDAQ) Stock Analysis | KINIKSA PHARMACEUTICALS LTD – Deepscope
MARKET

Select Market Data Region

KNSA — KINIKSA PHARMACEUTICALS LTD (Healthcare >> Drug Manufacturers - Specialty & Generic)

KNSA FAQ

What is KNSA's P/E ratio?

KINIKSA PHARMACEUTICALS LTD (KNSA) currently trades at a P/E ratio of 49.41.

What is KNSA's ROE?

KINIKSA PHARMACEUTICALS LTD reports a Return on Equity (ROE) of 12.06%.

What is KNSA's dividend yield?

KINIKSA PHARMACEUTICALS LTD offers a dividend yield of 0.00%.

What is KNSA's Deepscope Quality Score?

Deepscope rates KNSA's overall financial quality at 62 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy KNSA?

Deepscope's AI Timing Score for KNSA is 56 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does KNSA belong to?

KINIKSA PHARMACEUTICALS LTD is classified under the Healthcare >> Drug Manufacturers - Specialty & Generic sector on the NASDAQ exchange.

Stock Check   *Daily update data at 9:30 AM*
(Price: 2026-06-03 | FS: 2026-03-31)

KNSA

KINIKSA PHARMACEUTICALS LTD
USD 47.85
0.93 (1.98%) Day Change
49.41
P/E
0.01
D/E
12.1%
ROE
8.9%
ROA
0.00%
Div Yield
-0.20
PEG

KINIKSA PHARMACEUTICALS LTD
TYPE: STOCK
MARKET: NASDAQ

Compare   Watchlist   Myport
USD 47.85
Price
0.93 (1.98%)
Day Change
NEWS SCORE: 99

KNSA, the overall quality is ok ( Quality = 62) and the timing to buy is ...(Sign In to See)...

62

QUALITY

Signal
NEUTRAL
Signal Description
Company financial health is OK
Reason
P/E ratio is relatively high
ROE is relatively low.
Acceleration of ROE growth rate is below our criteria.
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria

88 Sign in

TIMING

Signal
OUTPERFORM
Signal Descri...
Good
Reason
Lorem ipsum dolor sit amet
Sign in to see timing analysis
Unlock timing signals and detailed reasons
Sign in free

In details, quality factors are not good , financial health is not quite good , and ability to make profit is not quite good , ...

Quality Factors 47%
X
X
X
X
  In Recommendations? Not in any sections
  Select Rate 0.00 From 30 days period
  Watch Rate 0.00 From 30 days period
  News Score 99
  Magic Formula Rank by ROA
1949
  Magic Formula Rank by ROE
1949
  Magic Formula Rank by ROIC
1492
  Price 47.85
  PBV / Sector
5.96 / 2.65
  Earning Per Share 0.97
  PE / Sector
49.41 / 22.64
  PEG or PE/Growth / Sector
-0.20 / 0.11
  Average 1M Daily Value
28.25 M
GREAT
  Average 1W Daily Value
29.28 M
GREAT
Timing Factors 42%
  MACD
  MACD Signal
  MACD Divergence
  RSI
  Stochastic Oscillator K
  Stochastic Oscillator D
  ADX
  Avg 5 day Timing Score
Financial Health 50%
X
X
X
X
  DE / Sector
  DE Average / Sector
  DE Change Average (%) / Sector
  Current Ratio / Sector
  Current Ratio Average / Sector
  Current Ratio Change Average (%) / Sector
  Quick Ratio / Sector
  Quick Ratio Average / Sector
  Quick Ratio Change Average (%) / Sector
  FCF/Share / Sector
  FCF/Share Average / Sector
  FCF/Share Change Average (%) / Sector
Ability to Make Profit 56%
X
X
X
X
X
X
X
  GPM (%) / Sector
  GPM Average (%) / Sector
  GPM Change Average (%) / Sector
  OPM (%) / Sector
  OPM Average (%) / Sector
  OPM Change Average (%) / Sector
  NPM (%) / Sector
9.69 / 15.98
  NPM Average (%) / Sector
19.34 / -16.38
GREAT
  NPM Change Average (%) / Sector
-140.91 / 113.39
  Asset Turnover / Sector
  Asset Turnover Average / Sector
  Asset Turnover Change Average (%) / Sector
  ROA (%) / Sector
8.85 / 8.16
  ROA Average (%) / Sector
10.34 / 2.38
  ROA Change Average (%) / Sector
-165.15 / 108.63
  ROE (%) / Sector
12.06 / -0.19
  ROE Average (%) / Sector
12.42 / 7.40
  ROE Change Average (%) / Sector
-172.38 / 371.95
  ROIC (%) / Sector
  ROIC Average (%) / Sector
  ROIC Change Average (%) / Sector
Return to Investors 4%
X
  Dividend (%) / Sector
N/A / 0.54
  Dividend Average (%) / Sector
N/A / 3.08
  Dividend Change Average (%) / Sector
N/A / 15.11
Registration Details
X
  Analyze Date 2026-06-04 09:24:15
  Symbol KNSA
  Name KINIKSA PHARMACEUTICALS LTD
  Sector Healthcare >> Drug Manufacturers - Specialty & Generic
  Market NASDAQ
  Listed Shares 46.30 M
  Par Value N/A
  Calculated From Quarter
  Sign N/A
  Market Cap (M.USD) / Sector Average 3,609.93 / 9,480.84
News, Concensus, ...
  Estimation Consensus See at WSJ.com
  Full details See at WSJ.com
  Chart See in Chart feature
  News See at Yahoo Finance

Address: 105 Piccadilly, London, United Kingdom, W1J 7NJ

Phone: 44 78 1431 9100

Website: https://www.kiniksa.com

Employees: 366

Sector: Healthcare >> Drug Manufacturers - Specialty & Generic

Description: Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.

ME vs SECTOR Healthcare >> Drug Manufacturers - Specialty & Generic

KNSA (ME)
Sector Peers
Bubble size = Market Cap

Click a bubble to view stock details  ·  Bubble size represents market capitalization share

News

Smart picks. Just WOW stocks/funds/ETFs. No noise like other tools.
KNSA
KNSA
USD 47.85 (1.98%)
+ Watch + Port Chart